



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** August 18 2010

**To:** Primary Clinical Research Associates

**From:** Linda S. Long  
Research Protocol Specialist III

**Re:** **N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma**

The Eligibility Checklist has been revised as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
Descriptive Factor	<ul style="list-style-type: none"><li>• Dose level -2a has been added to the checklist</li></ul>

If you have any questions, please feel free to contact me.

Enclosure